Immuno-oncology (IO) market – harnessing the immune system to fight cancer. The IO market was worth c.$7.4bn in 2016 – an increase of 159% over 2015 and driven by five products, the first of which was introduced in 2011. With the impending launch of AstraZeneca's Imfinzi for second-line bladder cancer and potentially first-line Stage 3 NSCLC later in the year, we forecast this class of compounds to grow to c.$18.1bn in 2018. These products (Keytruda, Opdivo, Imfinzi etc) represent
